Multiple antipsychotic medication prescribing patterns

被引:42
作者
Schumacher, JE
Makela, EH
Griffin, HR
机构
[1] William R Sharpe Jr Hosp, Dept Pharm, Weston, WV 26452 USA
[2] W Virginia Univ, Sch Med, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA
[3] W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA
关键词
antipsychotic; drug use evaluation; polypharmacy; psychosis; schizophrenia;
D O I
10.1345/aph.1C420
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess current prescribing practices regarding concomitant use of antipsychotic medications and summarize the reasons clinicians may prescribe >1 scheduled agent. Methods: The pharmacy identified patients at William R Sharpe Jr Hospital currently receiving antipsychotic therapy. All patients receiving greater than or equal to2 scheduled antipsychotic agents concomitantly were included in the study. Data regarding the demographics, current medication combinations used, history of therapeutic regimens tried, and prescriber rationale were prospectively evaluated for a 60-day period beginning December 13, 2000, and ending February 10, 2001. Prescriber rationale for using >1 antipsychotic simultaneously and other drug therapy regimens that had been tried were compared with chart documentation and published therapeutic guidelines for schizophrenia. Results: Over a 60-day surveillance period, 206 patients were placed on scheduled antipsychotic medications, with 85 (41%) receiving at least 2 agents. Responders to a prescriber questionnaire (59%) indicated the most common rationale for combination therapy was augmentation; the least likely rationale was cross-titration. Survey responses also indicated a belief that there was questionable therapeutic benefit in more than half of the patients being treated with multiple antipsychotic combinations. Additionally, chart documentation showed that the majority of these patients did not receive an adequate trial of monotherapy with other atypical or typical agents, or clozapine prior to the combination antipsychotic regimen. Fifty-one percent of medical records did not document the rationale for concomitant therapy. Conclusions: Due to the lack of published data, the practice of using multiple antipsychotic agents is considered to be a gray area that requires the prescriber to be at a heightened level of awareness in assessing effectiveness and safety. Documentation of rationale, adverse effects, and response to the treatment regimen is essential in providing optimal care for the patient.
引用
收藏
页码:951 / 955
页数:5
相关论文
共 18 条
[1]  
[Anonymous], 1977, INT CLASS DIS
[2]  
BOWEN GT, 2000, P T, V24, P297
[3]   DEFINING TREATMENT REFRACTORINESS IN SCHIZOPHRENIA [J].
BRENNER, HD ;
DENCKER, SJ ;
GOLDSTEIN, MJ ;
HUBBARD, JW ;
KEEGAN, DL ;
KRUGER, G ;
KULHANEK, F ;
LIBERMAN, RP ;
MALM, U ;
MIDHA, KK .
SCHIZOPHRENIA BULLETIN, 1990, 16 (04) :551-561
[4]  
CRISMON ML, 1999, PHARMACOTHERAPY PATH, P1118
[5]  
Ereshefsky L, 1999, J CLIN PSYCHIAT, V60, P20
[6]  
Herz MI, 1997, AM J PSYCHIAT, V154, P1
[7]  
Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1
[8]   Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system - Individual and facility predictors [J].
Leslie, DL ;
Rosenheck, RA .
MEDICAL CARE, 2001, 39 (09) :923-933
[9]   The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms [J].
Miller, AL ;
Chiles, JA ;
Chiles, JK ;
Crismon, ML ;
Rush, AJ ;
Shon, SP .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (10) :649-657
[10]   Management of treatment refractory schizophrenia [J].
Morrison, DP .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 169 :15-20